Related Experiment Videos

Pediatric stage IV Hodgkin disease. Long-term survival

S B Bader1, H Weinstein, P Mauch

  • 1Joint Center for Radiation Therapy, Harvard Medical School, Boston, MA.

Cancer
|July 1, 1993
PubMed

Insights

Combined-modality therapy (CMT), including chemotherapy and radiation therapy (RT), significantly improved freedom from progression (FFP) in children with Stage IVB Hodgkin disease (HD). This approach is favored over chemotherapy alone for advanced HD treatment.

Area of Science:

  • Pediatric Oncology
  • Hematology
  • Radiation Oncology

Background:

  • Optimal treatment for Stage IV Hodgkin disease (HD) is uncertain, especially the role of radiation therapy (RT).
  • Hodgkin disease is a cancer of the lymphatic system.
  • Stage IV HD indicates widespread disease.

Purpose of the Study:

  • To evaluate the effectiveness of combined-modality therapy (CMT) versus chemotherapy (CT) alone in treating pediatric Stage IV Hodgkin disease.
  • To determine if adding radiation therapy (RT) to chemotherapy improves outcomes in advanced HD.
  • To analyze progression-free survival (PFS) and overall survival (OS) rates.

Main Methods:

  • Retrospective review of 43 children (≤18 years) with Stage IV HD treated between 1970 and 1988.
  • All patients received combination chemotherapy (MOPP or MOPP plus other agents).
  • 20 patients received adjuvant radiation therapy (RT) after chemotherapy, forming the combined-modality therapy (CMT) group.

Main Results:

  • Seven-year actuarial freedom from progression (FFP) was 69% and survival was 78% for all patients.
  • Combined-modality therapy (CMT) significantly improved progression-free survival for patients with Stage IVB HD compared to CT alone (2 relapses vs. 8 relapses; P=0.003).
  • Patients achieving complete response (CR) to CT had better survival rates than those with partial response (PR), though not statistically significant.

Conclusions:

  • Combined-modality therapy (CMT), incorporating chemotherapy and radiation therapy (RT), demonstrated a significant benefit in freedom from progression for Stage IVB Hodgkin disease.
  • The addition of RT to chemotherapy appears crucial for improving outcomes in advanced pediatric Hodgkin disease, particularly for Stage IVB.
  • This retrospective analysis supports the use of CMT for Stage IVB HD.
Abstract

Related Concept Videos